Appointments: Shire, Bicycle Therapeutics, Gilead Sciences, Astellas, Alzheon, Alnylam and Amplyx
2017 begins with three Novartis executives finding new roles and high-level appointments made by Shire, Bicycle Therapeutics, Gilead Science and Amplyx Pharmaceuticals.
You may also be interested in...
CEO John Milligan offered few details about Gilead's deal strategy during an investor conference last week, but analysts think internal pressure for a major deal is beginning to equal the external sentiment, including an analyst who sees Incyte as a likely target, but not a quick fix for Gilead's declining HCV drug sales.
Company no longer has to worry about a US FDA advisory committee review, which the agency cancelled. Launch preparations include hiring 140 sales reps.
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.